Professional Media briefs: May 2014

Ivan Oransky
Ivan Oransky

BMJ and the Lupus Foundation of America have published the first articles for Lupus Science & Medicine, which the partners said is the first lupus-specific open-access journal. Lupus Foundation CEO and President Sandra Raymond said in a statement that the foundation's publishing efforts have been scattered across non-lupus publications and that this journal “provides a much needed, centralized home for… lupus research findings.”

MedPage Today's Ivan Oransky's Retraction Watch has launched a subscriber service. Oransky (pictured) and partner Adam Marcus announced the service in a March post, alerting readers that subscriptions to the four-year-old blog would go toward such things as paying writers and creating a database. Funds will be handled by a third party, so as to protect the site's independence.

John Wiley & Sons has updated its 2006 Best Practice Guidelines on Publishing Ethics: A Publisher's Perspective. The goal remains to be a touchstone for advice on what the company calls “the major ethical principles of academic publishing.” The new edition includes guidance about whistle-blowers, clinical trial registration and other subjects.

You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.